logo

VNDA

Vanda Pharmaceuticals·NASDAQ
--
--(--)
--
--(--)

VNDA fundamentals

Vanda Pharmaceuticals (VNDA) expects to report earnings on Feb 11, 2026, with estimated revenue of 59.27M (YoY +11.45%), and EPS at -0.975 (YoY -1118.75%).
Revenue estimate / YoY
59.27M
+11.45%
EPS estimate / YoY
-0.975
-1118.75%
Report date
Feb 11, 2026
Earnings Call
4:30 PM on Feb 11, 2026
Meeting link.
EPS
Revenue

Revenue & Expenses

VNDA has released its 2025 Q3 earnings report, with revenue of 56.26M, reflecting a YoY change of 18.06%, and net profit of -22.59M, showing a YoY change of -324.23%. The Sankey diagram below clearly presents VNDA's revenue sources and cost distribution.

Key Indicators

Vanda Pharmaceuticals (VNDA) key financial stats and ratios, covering profitability, financial health, and leverage.
Vanda Pharmaceuticals (VNDA)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown
Vanda Pharmaceuticals (VNDA)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown
Vanda Pharmaceuticals (VNDA)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown
Where does Vanda Pharmaceuticals (VNDA) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:
Track Vanda Pharmaceuticals (VNDA) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield